Trials / Recruiting
RecruitingNCT06368921
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics, Biological Effects and Initial Efficacy of Recombinant Oncolytic Virus M1 for Injection (VRT106) in the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.
Detailed description
This study is an open-label, dose-escalation clinical study which aims to evaluate the safety and tolerability of IT injections of VRT106 in subjects with locally advanced/metastatic solid tumors, as well as evaluating the biological distribution characteristics and biological effects of VRT106 (i.e., virus tissue distribution and shedding characteristics), evaluating immunogenicity of VRT106, and preliminarily exploring the anti-tumor effects of VRT106.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VRT106 | intratumoral injection |
Timeline
- Start date
- 2024-06-19
- Primary completion
- 2026-09-01
- Completion
- 2026-12-01
- First posted
- 2024-04-16
- Last updated
- 2025-12-30
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06368921. Inclusion in this directory is not an endorsement.